SelectedWorks - Mark Tidswell

Contact

Selected Works of Mark Tidswell

MD

Works
About

×

About Mark Tidswell

Present	MD, Baystate Health ‐ Department of Medicine
Institution Organization Position Type Position Title Time Period to Options Current Position Affiliate my profile with this Institution

Medicine and Health Sciences

A Randomised trial of anti-GM-CSF Otilimab in severe COVID-19 pneumonia (OSCAR) (Mark Tidswell) All Scholarly Works (2022)

Abstract BACKGROUND: Granulocyte-macrophage colony-stimulating factor (GM-CSF) and dysregulated myeloid cell responses are implicated in the pathophysiology and severity of coronavirus disease 2019 (COVID-19). Methods: In this randomised, sequential, multicentre, placebo-controlled, double-blind study, adults aged 18-79 ...

Variation in Early Management Practices in Moderate-to-Severe Acute Respiratory Distress Syndrome in the United States (Mark Tidswell) All Scholarly Works (2021)

Background: While specific interventions have previously demonstrated benefit in patients with the Acute Respiratory Distress Syndrome (ARDS), use of these interventions is inconsistent, and patient mortality remains high. The impact of variability in center management ...

Putative invasive pulmonary aspergillosis in apparently immunocompetent patients within medical wards and intensive care units (Babatunde Edun and Mark Tidswell) All Scholarly Works (2021)

Rapid Intensive Care Unit Onboarding in Response to a Pandemic (Fahad Alroumi, Jonathan Chinea, Nakul Ravikumar, et al.) All Scholarly Works (2021)

Background: In the wake of the coronavirus disease 2019 (COVID-19) pandemic, hospital resources have been stretched to their limits. We introduced an innovative course to rapidly on-board a group of non-intensive care unit (ICU) nurse ...

Safety Assessment of a Noninvasive Respiratory Protocol for Adults with COVID-19 (William Soares, Elizabeth Schoenfeld, Paul Visintainer, et al.) All Scholarly Works (2020)

As evidence emerged supporting noninvasive strategies for coronavirus disease 2019 (COVID-19)-related respiratory distress, we implemented a noninvasive COVID-19 respiratory protocol (NCRP) that encouraged high-flow nasal cannula (HFNC) and self-proning across our healthcare system. To assess ...

Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab (Mark Tidswell) All Scholarly Works (2019)

PURPOSE: Sepsis-associated immunosuppression increases hospital-acquired infection and viral reactivation risk. A key underlying mechanism is programmed cell death protein-1 (PD-1)-mediated T-cell function impairment. This is one of the first clinical safety and pharmacokinetics (PK) assessments ...

Prospective Assessment of the Feasibility of a Trial of Low-Tidal Volume Ventilation for Patients with Acute Respiratory Failure (Jay Steingrub and Mark Tidswell) All Scholarly Works (2019)

RATIONALE: Low-tidal volume ventilation (LTVV; 6 ml/kg) benefits patients with acute respiratory distress syndrome and may aid those with other causes of respiratory failure. Current early ventilation practices are poorly defined. OBJECTIVES: We observed patients ...

Prospective Assessment of the Feasibility of a Trial of Low Tidal Volume Ventilation for Patients with Acute Respiratory Failure (Jay Steingrub and Mark Tidswell) All Scholarly Works (2018)

RATIONALE: Low tidal volume ventilation (LTVV, 6 mL/kg) benefits patients with acute respiratory distress syndrome (ARDS) and may aid those with other causes of respiratory failure. Current early ventilation practices are poorly defined. OBJECTIVES: We ...

Use of the blood substitute HBOC-201 in critically ill patients during sickle crisis: a three-case series (Jonathan Davis, Nura El-Haj, Mark Tidswell, et al.) All Scholarly Works (2018)

BACKGROUND: Red blood cell (RBC) transfusion is an important treatment modality during severe sickle cell crisis (SCC). SCC patients who refuse, or cannot accept, RBCs present a unique challenge. Acellular hemoglobin (Hb)-based oxygen carriers (HBOCs) ...

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome (Mark Tidswell) All Scholarly Works (2017)

BACKGROUND: Renin-angiotensin system (RAS) signaling and angiotensin-converting enzyme 2 (ACE2) have been implicated in the pathogenesis of acute respiratory distress syndrome (ARDS). We postulated that repleting ACE2 using GSK2586881, a recombinant form of human angiotensin-converting ...

Nonlinear Imputation of PaO2/FIO2 From SpO2/FIO2 Among Mechanically Ventilated Patients in the ICU: A Prospective, Observational Study (Mark Tidswell and Jay Steingrub) All Scholarly Works (2017)

OBJECTIVES: In the contemporary ICU, mechanically ventilated patients may not have arterial blood gas measurements available at relevant timepoints. Severity criteria often depend on arterial blood gas results. Retrospective studies suggest that nonlinear imputation of ...

Randomized, Double-Blind, Placebo-Controlled Trial of Thiamine as a Metabolic Resuscitator in Septic Shock: A Pilot Study (Mark Tidswell and Howard Smithline) All Scholarly Works (2016)

OBJECTIVE: To determine if intravenous thiamine would reduce lactate in patients with septic shock. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Two US hospitals. PATIENTS: Adult patients with septic shock and elevated (> 3 mmol/L) lactate ...

Fluid Management With a Simplified Conservative Protocol for the Acute Respiratory Distress Syndrome* (Mark Tidswell) All Scholarly Works (2015)

OBJECTIVES:: In the Fluid and Catheter Treatment Trial (FACTT) of the National Institutes of Health Acute Respiratory Distress Syndrome Network, a conservative fluid protocol (FACTT Conservative) resulted in a lower cumulative fluid balance and better ...

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized trial (Mark Tidswell) All Scholarly Works (2013)

IMPORTANCE: Eritoran is a synthetic lipid A antagonist that blocks lipopolysaccharide (LPS) from binding at the cell surface MD2-TLR4 receptor. LPS is a major component of the outer membrane of gram-negative bacteria and is a ...

The effect of night time admission to a medical-surgical ICU (Mark Tidswell and Jay Steingrub) All Scholarly Works (2012)

Medical ethics, end of life care and clinical research (Jay Steingrub, Mark Tidswell and Paul Jodka) All Scholarly Works (2011)

Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis (Mark Tidswell) All Scholarly Works (2011)

The human innate immune system initiates inflammation in response to bacterial molecules, particularly Gram-negative bacterial endotoxin. The steps by which endotoxin exposure leads to systemic inflammation include binding to Toll-like receptor-4 that specifically recognizes endotoxin ...

Automated reporting of safety bundles: Streamlining the performance improvement process (William McGee, Thomas Higgins and Mark Tidswell) All Scholarly Works (2011)

The effect of loading dose timing of eritoran on 28-day mortality in patients with severe sepsis and higher risk of mortality: Analysis of data from a phase II trial (Mark Tidswell) All Scholarly Works (2011)

Pulmonary Fibrosis after chemotherapy with Oxaliplatin and Capecitabine for colorectal carcinoma (Geetika Sachdeva, Ashish Arora and Mark Tidswell) All Scholarly Works (2010)

28-day mortality in high-risk with severe sepsis receiving eritoran with or without drotrecogin alfa: Analysis of data from a phase II trial (Mark Tidswell) All Scholarly Works (2010)

Comparative efficacy of eritoran, a toll-like receptor 4 antagonist, in patients with severe sepsis and higher risk of mortality by type of causative pathogen (Mark Tidswell) All Scholarly Works (2010)

Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis (Mark Tidswell) All Scholarly Works (2010)

OBJECTIVES: Endotoxin is a potent stimulus of proinflammatory response and systemic coagulation in patients with severe sepsis. Endotoxin is a component of Gram-negative bacteria that triggers an innate immune response through Toll-like receptor 4 signaling ...

Racial and ethnic disparities in mortality from acute lung injury (Jay Steingrub and Mark Tidswell) All Scholarly Works (2009)

OBJECTIVE: Little is known about the influence of race and ethnicity on mortality from acute lung injury (ALI). We sought to determine whether black race or Hispanic ethnicity is independently associated with mortality among patients ...

Randomized clinical trial of activated protein C for the treatment of acute lung injury (Jay Steingrub and Mark Tidswell) All Scholarly Works (2008)

RATIONALE: Microvascular injury, inflammation, and coagulation play critical roles in the pathogenesis of acute lung injury (ALI). Plasma protein C levels are decreased in patients with acute lung injury and are associated with higher mortality ...